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Background: The GSK-3 genes (Gsk3a and Gsk3b) have been known to affect many 
cellular processes and signaling pathways some of which are implicated in the growth 
and development of the craniofacial skeleton. 
 
Aim: The purpose of this study was to assess the effect of chondrocyte-specific deletion 
of Gsk3a and Gsk3b on the size of the mandible and craniofacial skeleton in embryonic 
mice. 
 
Materials & Methods: Mice were bred to generate cartilage-specific Gsk3a and Gsk3b 
KO mice. On embryonic day 18.5 (E18.5) the offspring were gathered by caesarian 
section. Whole mount skeletal staining was completed on the specimens using Alcian 
blue and Alizarin red. The antero-posterior (AP) dimension of the entire craniofacial 
skeleton and the mandible was measured, along with the transverse dimension of the 
cranial vault and the intramandibular angle for each embryo. The investigator was blind 
to the genotype of embryos in each trial group. Immunohistochemistry was used to 
detect and localize three proteins, Sox9, Beta-catenin, and Osteocalcin, in the bone and 
cartilage of E16 mouse skulls. 
 
Results: The specific removal of both Gsk3a and Gsk3b in prenatal cartilage of mice 
leads to a significant reduction in the antero-posterior length of the total craniofacial 
skeleton and mandible when compared to wildtype mice. Cartilage-specific 
Gsk3a/Gsk3b KO mouse embryo display no significant change in the transverse width of 
the cranial vault. A significant increase in the intramandibular angle is seen in the KO 
mice when compared to the wild type mice.  
 
Conclusions: Loss of both GSK-3 isoforms in prenatal mice results in significant changes 
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Summary for Lay Audience 
Orthodontics is a field which utilizes bone growth to move teeth, expand the 
upper jaw, and to align the upper and lower jaws in a manner which is harmonious to 
the rest of the skull. Currently mechanical approaches employing brackets, wires, 
auxiliaries, appliances, and surgical methods are the primary means to manipulate bone 
growth and achieve orthodontic goals. With advances in molecular medicine research, 
biological approaches including molecular therapy may provide new avenues to 
manipulate bone growth. Molecular interventions such as those that target GSK-3, an 
enzyme involved in skeletal development, may assist orthodontists to treat patients in 
which unstable dental camouflage or orthognathic surgery are the only viable options. 
Previous studies have looked at the way the GSK-3 genes affects bone growth, which is 
commonly done by removing the gene. This study was designed to see if removing both 
GSK-3 genes from a specific structural component (cartilage) in mice before they are 
born would change the shape and size of their head or lower jaw. Multiple prenatal 
mouse skulls were measured using images taken on a microscope of skulls stained to 
make bone more conspicuous. The measurements of the mice missing the GSK-3 genes 
were compared to normal mice gathered from the same litter. This study found the 
mice which had the GSK-3 genes removed had a smaller head size in length but not in 
the width dimension. The mutant mice also had a smaller bottom jaw in the length 
dimension but bigger in the angular width dimension. This study showed that the GSK-3 
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Chapter 1  




In 1980 an enzyme that inactivated glycogen synthase, a key regulator of 
glycogenesis, was discovered in rabbit skeletal muscle cells.1 At the time its only known 
role was the regulation of glycogenesis. It was consequently named glycogen synthase 
kinase 3 (GSK-3). Initially, GSK-3 did not garner much attention from the research 
community. It was not until a decade later in 1992 when Hanger et al’s research on tau 
phosphorylation first shone the spotlight on GSK-3 and identified GSK-3 as being a key 
contributing enzyme in the abnormal phosphorylation of the microtubule associated 
protein tau. Tau itself is responsible for the development of neurofibrillary tangles seen 
in Alzheimer’s disease.2 Another advance in research 4 years later found that the 
commonly prescribed bipolar disorder medication lithium selectively inhibited GSK-3.3 
With this knowledge, pharmaceutical companies and research groups began to focus 
their efforts on preparing GSK-3 as a therapeutic target.4, 5 Current literature now 
recognizes that GSK-3 has a role in multiple signalling pathways including regulation of 
cell development, cellular architecture, the cell cycle, and apoptosis.6 Due to its broad 
spectrum influence it has been linked to a diverse array of diseases including diabetes 
and insulin resistance, cancer, rheumatoid arthritis and Alzheimer’s disease.6 
 
1.2 GSK-3 Structure 
 
The enzyme is a serine/threonine kinase that is conserved across all eukaryotes 
and is expressed in almost all tissue types.7 In primitive organisms like nematodes, GSK-
3 is encoded by a single gene. In mammals, GSK-3 is present as two specific proteins, 
GSK-3α and GSK-3ß, which are homologous proteins derived from different genes.7 





GSK-3ß2.8 GSK-3ß2, unlike the other two ubiquitous isoforms, is primarily expressed in 
neuronal tissue and currently has an unclear role. Among vertebrates, only birds share 
this property, retaining the GSK-3ß protein.9 It is believed that the evolution of GSK-3 
isoforms is linked to the rise of vertebrates and in particular the development of their 
central nervous system.5 The molecular weight of GSK-3α protein is 51 Kilodaltons, 
while GSK-3ß is 47 Kilodaltons, the disparity due to a glycine rich extension present at 
the N-terminus of GSK-3α.10 The structure of GSK-3’s catalytic domain contains a N-
terminal domain comprised of β-strands in a β barrel conformation and a C-terminus 
comprised of α-helices.11 The general structure is akin to other protein kinases.11 
Between the N and C terminus is the C-helix and activation loop, which together create 
the binding site for the substrate to receive the gamma phosphate from ATP in the 
process of phosphorylation.12 At the substrate binding site both GSK-3α and GSK-3ß 
possess lysine residues which catalyze the transfer of gamma phosphate to the 
substrate.13 It has been shown through point mutation of specific residues that the N-
terminus is expendable, whereas, the deletion of the C-terminus creates destabilization 
of GSK-3’s tertiary structure.13 It is believed that targeting the C-terminus is key to 
creating an isoform-specific GSK-3 therapeutic inhibitor.13 Despite being structurally 










1.3 Function and Regulation 
 
GSK-3 predominantly functions as a negative regulator in numerous anabolic 
pathways.14 It has also been known to modulate cell proliferation, differentiation, 
neuron development, immune and inflammatory response, and bone formation. GSK-3 
has been linked to the canonical Wnt/Beta-catenin pathway15, the osteogenesis-
associated Runx2 pathway16, Hedgehog signalling pathway17 and many others.18 The 
primary mechanism in which GSK-3 acts is through phosphorylating proteins in cellular 
pathways and inhibiting their downstream effect.14 An unusual characteristic of GSK-3 
compared to other protein kinases is its preference for primed substrates that have 
been acted upon by another kinase. GSK-3’s affinity for pre-phosphorylated substrates is 
seen as another potential target point for therapeutic inhibitors.19 In certain pathways 
like the Wnt/beta catenin pathway both isoforms are functionally redundant.20 This was 
demonstrated when Doble et al. found Wnt/beta catenin signaling to be normal despite 






an absence of compensatory upregulation in GSK-3 protein levels in embryonic stem 
cells deficient of either the GSK-3α or GSK-3ß isoform alone.20 Only when cells lacked 
alleles for both isoforms was beta catenin signaling affected.20 In other pathways the 
individual influence of each isoform is less clear.21  
Another atypical characteristic of GSK-3 is that in its basal state it is constitutively 
active in cells and is generally rendered inactive upon phosphorylation 14. Regulation 
through phosphorylation of both isoforms occurs at two sites involving either a tyrosine 
or serine residue. Inactivation of GSK-3 occurs when the N-terminus is phosphorylated 
at Ser-9 in GSK-3ß or Ser-21 in GSK-3α.22 Kinases that are known to inhibit GSK-3 
through phosphorylation of serine include protein kinase A, PI3 kinase regulated 
Akt/PKB, p70 S6 kinase, and protein kinase C.15 On the other hand, GSK-3 activity is 
augmented when tyrosine phosphorylation of Tyr-216 in GSK-3ß, and Tyr-279 in GSK-3α 
occurs in the catalytic domain.22 Kinases known to phosphorylate tyrosine residues and 
increase enzymatic activity of GSK-3 include Fyn, Pyk2, and Csk.22 Regulation of GSK-3 
can also be independent of serine or tyrosine phosphorylation, although uncommon, is 
a mechanism retained by the Wnt signaling pathway. GSK-3 antagonizes the canonical 
Wnt signalling pathway 23, thus for the Wnt pathway to function it requires 
downregulation of GSK-3. The mechanism which is not fully understood is believed to 
occur through complex formation via protein:protein binding interactions and 
sequestration of GSK-3 inside multivesicular endosomes. The capture of GSK-3 in 
endosomes likely prevents it from accessing its many cytosolic substrates.17, 24  
Additionally, regulation of GSK-3 can be completed through intracellular 
localization. The activity level of GSK-3 varies depending on its compartmental 
localization. Although GSK-3 is more abundant in the cytoplasm, it is also present in the 
nucleus and mitochondria where it is more active.25 The movement of GSK-3 outside of 
the nucleus has been shown to correlate with a decrease in phosphorylation of GSK-3 
nuclear substrates.25 Cellular processes like apoptosis have been associated with an 
increase in the nuclear localization of GSK-3. Exporting GSK-3 out of the nucleus is one 





survival.26 Frat/GBP (frequently rearranged in T-cell lymphomas/GSK-3 binding protein) 
is a binding protein known to regulate GSK-3 localization by facilitating its nuclear 
export. One of the potential targets for therapeutic isoform inhibitors is believed to be 
the N-terminal region of GSK-3, which contains the ATP-binding domain and also 
contributes to the localization of GSK-3. A study conducted by Azoulay-Alfaguter et al. 
found that while GSK-3ß normally moves between cytoplasm and the nucleus, GSK-3α is 
barred from the nucleus, a characteristic exclusive to mammalian GSK-3α.27 The 
researchers found that by deleting the glycine rich N-terminus of GSK-3α, the alpha 
isoform accumulated in the nucleus. They hypothesize that GSK-3 isoform regulation via 
localization is mediated by the glycine rich N-terminus, which is only present in GSK3-
α.27 
 
1.4 Mice Knockout Models 
 
Research shows when the Gsk3b isoform is made inoperative (global knockout) 
in mice it results in craniofacial abnormalities and embryonic lethality due to severe liver 
degeneration28, 29, in contrast to global Gsk3a knockout mice which are viable and have 
no visible craniofacial defects.21, 30 Furthermore, mice which are heterozygote for Gsk3b 
are viable, but present with increased anxiety, reduced exploration, and skeletal bone 
mass changes similar to those displayed in cleidocranial dysplasia (CCD).16, 31, 32 The 
viability of mouse embryos displaying increased activity of GSK-3ß was tested by Deak et 
al. in a glycogen synthase kinase 3ß interaction protein (GSKIP) model.33 GSKIP 
conventionally facilitates the serine phosphorylation of GSK3-ß by Protein Kinase A 
(PKA) thereby reducing GSK-3ß activity. In this model, GSKIP deficient mutant mice 
embryos at day 10.5 (E10.5) display increased GSK-3ß activity, which ultimately leads to 
failure of palatal shelf fusion and perinatal lethality.33 The phenotypic outcome of GSKIP 
deficient mice, however, differs from knock-in transgenic mice which display a 
constitutively active GSK-3ß that is immune to phosphorylation.34, 35 These transgenic 
mice are viable and show no craniofacial defects but do exhibit neuronal deficiencies 





Organ specific ablation of GSK-3 elucidates the importance of GSK-3 regulation 
throughout the body. Howard et al. demonstrated this concept when renal proximal 
tubule specific Gsk3b knockout mice conditioned to nephrotoxic injury displayed 
accelerated cell proliferation and healing.36 Moreover, the phenotype that is expressed 
in knockout mice can vary depending on the cells in which GSK-3 is deleted. In 
chondrocyte-specific GSK-3ß deficient mice the phenotype that is demonstrated is the 
same as wild-type mice, aside from elevated GSK-3α enzyme levels.37 The absence of 
skeletal abnormalities may indicate a compensatory mechanism by GSK-3α.37 The 
summation of current literature shows that the phenotype and clinical manifestation of 
the GSK-3 mutant does not strictly depend on whether the GSK-3 enzyme is present or 
not. It depends on a variety of factors including the timing of the ablation, post-natal or 
prenatal, the pathway by which GSK-3 is altered, the organ in which the enzyme is 
affected, the cells in which it is removed and the isoform which is targeted. All this 
information must be taken into consideration in order to develop therapies that target 
GSK-3 with safe clinical outcomes. 
 
1.5 Craniofacial Skeleton 
 
One of most unique and identifying structures in humans and mammals is the 
craniofacial complex. The complex consists of the head, the face and the oral cavity. 
Each constituent of the craniofacial complex can be categorized into its skeletal 
subcomponent. The posterior portion of the complex is comprised of the cranium a 
structure formed by the conjunction of the cranial vault and the cranial base.38 The 
anterior portion, the face, is comprised of the nasomaxillary complex and the mandible. 
The development of the craniofacial skeleton occurs through both endochondral and 
intramembranous ossification.  
Endochondral ossification is a process which begins when mesenchymal stem 
cells differentiate into chondroblasts to form a cartilage intermediate.39 Chondroblasts 
differentiate into chondrocytes which secrete alkaline phosphatase, an enzyme that acts 





chondrocytes undergo apoptosis and create cavitations which are invaded by blood 
vessels. The blood vessels serve as a source for osteoprogenitor cells, which 
differentiate into osteoblasts that produce bone mineral around the cartilage 
template.39 Intramembranous ossification, unlike endochondral ossification, does not 
require the formation of a cartilage template. Instead, the process involves 
mesenchymal stem cells differentiating directly into bone matrix depositing 
osteoblasts.40 
   The cranial base is sculpted by endochondral ossification of the 
chondrocranium, which is the cartilaginous structure derived from mesoderm that 
serves as a template to be replaced with new bone.38, 41 On the other hand, the cranial 
vault develops through intramembranous ossification. This process involves either 
paraxial mesoderm (parietal bones) or neural crest derived mesenchymal cells (frontal 
bones) that condense to produce osteoblasts which deposit osteoid matrix.38, 41 Fate 
mapping and lineage tracing in mice show that the bones which make the 
viscerocranium including the maxilla and mandible are formed from neural crest cells 
(NCC) that have localized to the first pharyngeal arch.42, 43 The NCC undergo both 
intramembranous and endochondral ossification.38 During embryogenesis neural crest 
cells migrate towards the developing brain and into the first three pharyngeal arches, 
which further develop to form the facial skeleton.38 The anatomical and physiological 
formation of the pharyngeal arches has been highly conserved through vertebrate 
evolution, with only the number of arches varying between species.44 The first arch 
gives rise to the maxilla and mandible, two structures which articulate together to give 
mammals the ability to perform mastication, respiration, and vocalization.44 Both the 
upper and lower jaw are formed during embryogenesis from their respective anatomical 
prominences located in the first pharyngeal arch. These prominences include the 
frontonasal, medionasal, nasolateral, maxillary, and mandibular prominence. Through 
systematic and unified development, the prominences fuse to form the face. Failure of 











1.6 Prenatal Growth of the Mandible 
 
The elements influencing the final arrangement of the mandible are more convoluted 
than those of the cranial vault. The shape and growth rate of calvaria bone is primarily 
governed by brain enlargement and cranial sutures.47 The mandible is a unique structure 
of the craniofacial complex in that it is formed from both intramembranous and 
endochondral growth.48 The mandible develops from the neural crest cells which have 
migrated to the first pharyngeal arch (mandibular arch). The NCC respond to signals from 
the primary germ layers of the first pharyngeal arch, to first condense, then differentiate 
into chondrocytes and osteoblasts.38 The chondrocytes organize into two hyaline based 
bilateral cartilaginous rods which are referred to as Meckel’s cartilage (MC). In mice MC 
forms at approximately E12.5 and begins to degenerate at E16.49 The proximal ends of 
MC form the bilateral template for the malleus and incus bones of the middle ear.48 
Whereas the distal ends of MC converge and fuse, to eventually form the template for 
the symphysis of the mandible48. The molecular mechanisms which control the 
development and regression of MC are still unclear 48, however, it is well established that 











Research shows that in the absence of MC the mandible still does form with relatively 
normal gross morphology and bone formation. However, the mandibles in mutant mice 
lacking MC are smaller, suggesting MC influences the size and not the initiation of bone 
formation.51 The body of the mandible ossifies through intramembranous bone growth 
on the outer surface of MC, with the first sign of osteoid tissue at the paired plates being 
seen at E13.5.49 By E16.5 both mandibular plates lengthen to meet at the symphysis and 
have enclosed the alveolar nerve and MC in the process.49 The mandible ossifies from its 
external aspect inward surrounding MC concomitantly as it grows along the antero-
posterior axis.49 The formation of the condyle and coronoid process occurs through 
endochondral ossification, these structures do not rely on the scaffold provided by 
Meckel’s cartilage.38 They instead, rely on mandibular condylar cartilage (MCC), which is 
classified as secondary cartilage. The axial and appendicular skeleton, by contrast, 
develop through the scaffold provided by primary cartilage.38  
Primary and secondary cartilage differ histologically and in place of origin. Secondary 
cartilage at the condyle histologically presents as undifferentiated prechondroblasts, with 
the cell pattern of proliferation being appositional. Primary cartilage has chondrocytes 
that demonstrate interstitial cell proliferation.52, 53 Both primary and secondary cartilage 
contain type II collagen, however, only secondary cartilage contains type I collagen, a 
component which functions to provide tensile strength for the extracellular matrix.54 
Primary cartilage develops from the primordial skeletal cartilage, whereas secondary 
cartilage at the mandible is believed to develop from alkaline phosphatase (ALP) 
expressing progenitor cells located on the periosteum.55, 56 A study conducted by Shibata 
et al. described the endochondral ossification of the condyle as similar to that found in 
long bones.56 At E14.5 chondrocytes located in MCC undergo hypertrophy followed by 
calcified bone tissue forming a bone collar around the MCC.56 The hypertrophic 
chondrocytes undergo apoptosis, leaving gaps in the mineralized extra cellular matrix. 
These openings are the cartilage lacunae which serve as the port of entry for blood 
capillaries to invade bringing in osteogenic cells. The osteogenic cells differentiate into 





condyle.56 Histologically, secondary cartilage is first detected at E14.5, with endochondral 
bone formation at the condyle occurring at E16.56 Intramembranous ossification 
contributes to the initial stages of mandible development with the later stages 
undergoing endochondral ossification of the secondary cartilage and developing into the 
condyle and angular process of the mandible.57 MCC will serve as the site for 




Figure 3: Mandibular growth over time measured from point Articulare (AR) to point 
Menton (Me).59 
 
 A variety of factors influence overall growth of the mandible including fetal jaw 
movement prenatally. In humans the jaw-opening reflex initiates at week 8.5, while in 
mice prenatal jaw movement begins at E16. Studies have shown that restricting fetal jaw 
movement reduces endochondral ossification of the condyle which can ultimately inhibit 
normal mandibular growth.60, 61 Experiments examining mice post-natally at 3 weeks of 
age until 33 weeks of age have demonstrated that the size and shape of the mandible in 
mice may be dependent on the consistency of the food they eat.62 Another study found 
that continuously trimming the lower incisors by 1mm increased posterior condylar 
growth during the posterior axial rotation of the condyle as the mandible was advanced. 
63 The environment seems to play an important role in the growth and development of 
the mandible both prenatally and postnatally. While researchers and clinicians have 





whether that be through a Herbst or a bilateral sagittal split osteotomy, the new path 




Figure 4: Anatomy of the mouse mandible in the sagittal viewpoint. Dashed line divides 




1.7 GSK-3 Regulated Pathways and Bone Growth 
 
 Genetics plays a major role in craniofacial and mandibular growth. GSK-3 is known 
to modulate transcription and growth factors involved in prenatal bone growth. Facial 
development is influenced by the Wnt signaling pathway, which is in turn regulated by 
GSK-3. During growth, structures of the face react to Wnt signaling with enhanced cell 
proliferation in order to increase mass. Studies show that vertebrates with a pronounced 
midface such as avian and mice species show increased Wnt responsiveness at the 
midline zone within the frontonasal process supporting more of an antero-posterior 
growth pattern of the face.45, 65 In humans, by contrast, Wnt signalling in the maxillary 
and mandibular processes leads to the development of flat, broad midfaces and results 





Sox9 is a transcription factor that regulates chondrocyte differentiation from 
mesenchymal cells, a process that is critical for endochondral ossification during 
embryogenesis.66 Literature shows that Sox9 knockout mice do not form MC, and 
although the mandible does form, it is much smaller than in control mice.51 Sox9 is a well-
known substrate of GSK-3. Phosphorylation of Sox9 by GSK-3 facilitates the binding of 
FBW7 which subsequently results in the ubiquitination and degradation of Sox9. 
Interestingly removal of GSK-3 from different germ line cells can change Sox9 levels. Bali 
et al. found that post-natal cartilage-specific GSK-3 deficient mice show decreased levels 
of Sox9 in growth plate and articular cartilage and skeletal growth retardation.67 Gillespie 
et al. found that bone-specific knockout of Gsk3b resulted in mice with shorter bones and 
dwarfism similar to cartilage-specific Gsk3 KO mice, despite Sox9 being upregulated in the 
cartilage of these mice.68 In vitro pharmacological inhibition of GSK-3 by contrast shows 
increased bone growth.37 The authors propose that the contradictory results may be due 
to a complex interplay of local skeletal effects and metabolic changes in GSK-3 deficient 
mice.68  
Runx2 is another osteogenesis modulator known to be regulated by GSK-3. Runx2 is a 
transcription factor that regulates expression of genes involved in the development of 
teeth, as well as intramembranous and endochondral bone formation.69 Haploinsuffiency 
in the Runx2 gene results in compromised osteogenesis and clinical manifestations of 
cleidocranial dysplasia (CCD) in both humans and mice.70 Kugimiya et al. used Runx2 
deficient mice to demonstrate Gsk3b’s ability to suppress Runx2’s transcriptional activity. 
The researchers crossed mice to produce Runx2+/- heterozygotes which displayed 
characteristics resembling human CCD, including delayed closure of the fontanelles and 
hypoplastic clavicles. They then administered lithium chloride (a selective inhibitor of 
GSK-3ß) to the embryos through the pregnant dams, orally starting at E7.5 to 3 weeks of 
age. At 3 weeks of age they found the GSK-3ß inhibitor to have rescued the Runx2+/- 
deficient mice from displaying CCD characteristics.16 The authors believe that attenuation 
of Runx2 by phosphorylation via GSK-3 is just one of many molecular pathways that GSK-





A study conducted by Kapadia et al. brings light to the variable effects of GSK-3, 
which is commonly shown to inhibit signaling needed for bone development. Fibroblast 
growth factor 18 (FGF18) was identified as a potential mediator of GSK-3 activity in 
metatarsal culture. In this study researchers harvested metatarsals from E15.5 embryos 
and treated them in organ culture with two GSK-3 inhibitors, lithium or SB216763. The 
researchers found that by inhibiting GSK-3 there was a significant reduction in 
chondrocyte and osteoblast differentiation, and chondrocyte proliferation, but there 
was a contrasting increase in perichondrial cell proliferation. The researchers 
hypothesized that the inhibition of GSK-3 induced Wnt/Beta catenin signaling, a 
pathway which is known to have complex effects displaying both an increase and 
decrease of chondrocyte differentiation. Kapadia et al. found that stimulation of the 
metatarsals with FGF18 produced a similar phenotype to GSK-3 inhibition. To determine 
whether metatarsal endochondral bone growth changes resulting from GSK-3 inhibition 
were mediated by changes in FGF18 expression, the researchers inhibited GSK-3 in 
metatarsals deficient of FGF18 receptors. The experiment revealed that inhibition of 
GSK-3 in metatarsals lacking FGF18 receptors did not reproduce the phenotype 
produced in metatarsals with normal FGF18 receptor expression. The researchers 
concluded that one of the molecules through which GSK-3 regulates endochondral bone 
growth is by mediation of FGF18.71 
NCC play a vital role in the development of craniofacial skeleton, particularly the 
viscerocranium. The movement of NCC into the first pharyngeal arches initiates their 
differentiation into cells which will eventually form the bone and cartilaginous tissue of 
the viscerocranium. Recent literature suggests GSK-3 plays a role in the migration of 
NCC from the neural tube to the first branchial arch (mandibular arch). Malagon et al. 
established that deletion of neural crest-specific GSK-3α and GSK-3ß immobilizes the 
NCC in the neural tube. Failure of migration of NCC to the facial prominences and 
branchial arches due to in vivo loss of GSK-3α and GSK-3ß resulted in fatality of the mice 
by E11.5.72 In order to examine the developmental effects of GSK-3 on NCC migration 





inhibitor 6-bromoindirubin-3’-oxime (BIO) between stages 12.5 and 19. They found that 
inhibition of GSK-3 resulted in concurrent loss of twist1 expression. Changes in face 
shape were illustrated including narrowing of the transverse width of the head, a 
decrease in the antero-posterior dimension anterior to the eye, and loss of the oral 
cavity. Discontinuing treatment of the GSK-3 inhibitor at stage 19 allowed for some 
recovery of twist1 expression, which corrected the craniofacial size abnormalities to 
some degree. 72 The relationship between GSK-3 and twist1 expression could provide 
valuable information in the treatment of Saethre Chotzen syndrome, a disorder 
characterized by craniosynostosis and syndactyly with many individuals expressing a 
mutation in the TWIST1 gene. 
Other factors involved in bone development and craniofacial growth include Sonic 
hedgehog (Shh), Bmp4, and endothelin-1. Current literature shows that GSK-3 has been 
implicated in the regulation of these signalling pathways in other physiological systems 
73,74, 75, however, there is not enough research linking these factors to GSK-3 in the 
realm of craniofacial growth and development. There is no direct evidence in the 
current literature associating mandibular growth, a process governed by 
intramembranous and endochondral ossification, with GSK-3. GSK-3 is, however, an 
enzyme which regulates bone developmental pathways, and many genes that are 
substrates of GSK-3 have been shown to impact mandibular growth.76–79 
 
1.8 GSK-3 and Dental Applications 
 
A great deal of research is focusing on mapping the effects of GSK-3 for clinical use. 
Inhibitors of the enzyme are being investigated for potential in treating diabetes4, 
Alzheimer’s disease 80, osteoporosis 81, as well for dental and orthodontic applications 
82. Many of the GSK-3 inhibitors including lithium, L803-mts, and Tideglusib, upregulate 
the Wnt signaling pathway and increase Beta-catenin levels, a protein which is known to 
have a positive effect on bone anabolism.5, 19, 83 In the field of dentistry an investigation 





dentine.84 To evaluate the remineralization effects of GSK-3 inhibitors researchers 
created a site of injury just above the pulp in mice molars using a dental bur, then 
inserted a sponge soaked with a GSK-3 inhibitor into the prepped site and left it for 4-6 
weeks. Three GSK-3 inhibitor experimental groups were compared to a control and a 
mineral trioxide aggregate (MTA) treatment group. At the end of the study period, the 
researchers found that the GSK-3 inhibitor groups had 2 times greater reparative 
dentine mineralization than the control and 1.7 times greater than the MTA group. 
Furthermore, the researchers calculated the equivalent dose of Tideglusib (GSK-3 
inhibitor) in humans and found the dose required for human tooth remineralization 
would be far below the allowed maximum systemic concentration.84  
Research has also shown that GSK-3 can modulate both local and systemic 
inflammation.85 Data on this subject can prove to be vital in learning how to treat 
bacteria-induced periodontitis. Adamowicz et al. used a previously established 
Porphyromonas gingivalis (P.gingivalis)-induced bone loss model to examine the effects 
of SB216763 (GSK-3 inhibitor) on the inflammatory response that characterizes 
periodontitis. The researchers discovered that mice treated with SB216763 had 
significantly less bone loss compared to the P.gingivalis bone loss group. The clinical 
findings were reinforced with immunohistochemistry and an evaluation of inflammatory 
mediators which indicated a decrease in systemic cytokines, local neutrophil infiltration, 
and IL-17 expression.86 The results indicate that alveolar bone loss can be decelerated 
by a GSK-3 inhibitor, putatively via modulation of the immune system.  
Moving teeth in orthodontics uses mechanical loading to generate a localized 
inflammatory reaction that triggers bone remodeling; controlling this inflammatory 
response through GSK-3 could possibly alter the speed in which teeth move. 
Orthodontic studies have examined the use of GSK-3 inhibitors on force-induced bone 
formation. The results of Mao et al. have shown an increase in bone formation after the 
local delivery of lithium on the tension side of teeth during orthodontic tooth 
movement.87 One of the primary reasons for relapse after maxillary expansion is skeletal 





also shown positive effects of GSK-3 inhibitors on enhancing bone growth during palatal 
expansion. Tang et al. assessed the effects of lithium fed orally in rats during midpalatal 
expansion and found there to be an increase in new bone formation during expansion.88 
Similarly, Jiang et al. found that the GSK-3 inhibitor SB-415286 stimulated new bone 
formation in the premaxilla when delivered locally by injection during the process of 
expansion.89 Together these studies show the potential for targeting GSK-3 to improve 
the outcomes of orthodontic treatment.  
 
1.9 Problem Statement 
 
Despite GSK-3’s vast sphere of influence on numerous cellular processes, and the 
research community’s great interest in the enzyme, there are only a limited number of 
studies assessing GSK-3’s role in the development of the craniofacial complex. 
Furthermore, there are even fewer studies assessing the cartilage-specific effects of 
GSK-3 on the prenatal formation of the craniofacial complex. The field of orthodontics 
prides itself in achieving harmony and balance between the bones of the viscerocranium 
and the cranial base, a paradigm emphasized in the 60s by Enlow et al. 90 which still 
stands today. Studying the effects of GSK-3 on the formation of the bones of the head 
can assist in providing new treatment modalities geared at correcting skeletal 
discrepancies whether they be craniosynostosis, hemifacial microsomia, or a 
retrognathic mandible.  
 
1.10  Purpose 
 
The primary purpose of this in vitro investigation is to assess the effect of 
chondrocyte specific deletion of Gsk3a and Gsk3b in embryonic mice on the size of the 
mandible and the antero-posterior (AP), and transverse size of the prenatal craniofacial 
skeleton at E18.5. A greater understanding of the role of GSK-3 in the determination of 
the size of the cranium and mandible may contribute to the development of GSK-3 





1.11  Hypothesis 
 
Gsk3a and Gsk3b knockout mice will have a smaller AP length of the mandible and 
skull as well as a smaller transverse width compared to the control mice. Gsk3a and 







Chapter 2  
2 Materials and Methods 
 
 
2.1 Mouse Breeding 
 
Floxed mice (Mus musculus) Gsk3afl/fl and Gsk3bfl/fl contain the DNA sequence for 
Gsk3a and Gsk3b flanked by LoxP sites, DNA sequences that undergo recombination in 
the presence of Cre recombinase (Cre+). The generation of floxed Gsk3afl/fl and Gsk3b fl/fl 
and transgenic mice expressing Cre recombinase under the control of the mouse type II 
collagen promoter (Col2a1) has been described elsewhere 30, 91, 92. Mice homozygous for 
both Gsk3afl/fland Gsk3bfl/fl alleles were generated (Gsk3afl/flGsk3bfl/fl) by first breeding 
the individual floxed lines to each other.  The progeny of this mating would be 
heterozygous for each floxed allele (Gsk3afl/+Gsk3bfl/+). The desired homozygotes are 
produced by breeding heterozygotes to each other. The homozygous floxed mice 
(Gsk3afl/flGsk3bfl/fl) were then crossed with mice expressing Cre recombinase under the 
control of the mouse Col2 1 promoter to produce Gsk3afl/+Gsk3bfl/+ Col2 1Cre+/- mice. 
These mice were then backcrossed with homozygous Gsk3afl/fl Gsk3bfl/fl mice to generate 
Gsk3afl/+Gsk3bfl/fl Col2 1Cre+/- mice. Male Gsk3afl/+ Gsk3bfl/flCol2 1Cre+/- were bred to 
female Gsk3afl/flGsk3bfl/fl to generate the offspring that were examined. The offspring 
genotypes were: Gsk3afl/flGsk3bfl/fl (control), Gsk3afl/+ Gsk3bfl/fl (control), Gsk3afl/+Gsk3b 
fl/fl Col2 1Cre+/- (alpha heterozygote) and Gsk3afl/flGsk3bfl/fl Col2 1Cre+/- (knockout). On 
embryonic day 18.5 (E18.5) the pregnant dams were euthanized by CO2 inhalation and 
the offspring were gathered by caesarian section. All procedures involving the mice in 
this study were approved by Western University’s Animal Care Committee and the 







2.2 PCR and Genotype Determination 
 
Genotype of the offspring was determined by polymerase chain reaction (PCR) 
utilizing DNA from soft tissue samples obtained from the skin of each embryo. PCR for 
genotyping uses primers specific to the GSK-3 allele being studied, the process amplifies 
the normal or mutant allele which is then observed and analyzed as bands after agarose 
gel electrophoresis. Primer sets were used to detect the presence of floxed Gsk3a, 
floxed Gsk3b and cre recombinase. The primer set 5’- CCCCCACCAAGTGATTTCACTGCTA 
-3’ and 5’- CTTGAACCTTTTGTCCTGAAGAACC -3’ was used for Gsk3a, 5’- 
GGGGCAACCTTAATTTCATT -3’ and 5’- GTGTCTGTATAACTGACTTCCTGTGGC -3’ for Gsk3b, 
and 5’ CCT GGA AAA TGC TTC TGT CCG 3’ and 5’ CAG GGT GTT ATA ACA ATC CC 3’ for 
Cre recombinase. The PCR protocol starts with an initial denaturation step at 95 °C for 3 
minutes, followed by 35 cycles of denaturation-annealing and extension (95°C, 15 
seconds; 60°C, 30 seconds; 72°C, 1 minute). A final extension step of 72°C for 10 
minutes, followed by 4°C maintenance step completes the reaction. The amplified DNA 
was then assessed on a 1.5% agarose gel, Gsk3a floxed alleles display a band of 650bp 
whereas the wild type allele of Gsk3a was 500bp. Gsk3b floxed alleles display a band of 
700bp versus a wild type allele of 500bp. Cre recombinase positive animals display a 
single band of 391bp. Mice without Cre recombinase show no band. Genotype was 




2.3 Skeletal Staining 
 
Whole mount skeletal staining allows one to evaluate the shape and size of 
skeletal components. The process differentially stains bone and cartilage, as a result one 
can assess the constituents and maturation level of the specimen. The cationic dye 
Alcian blue binds glycosaminoglycans and glycoproteins secreted by chondrocytes 





calcium ions, a metal which is highly concentrated in bone. Visually, bone is stained red, 
and cartilage is stained blue on the specimen.93 At E18.5 embryonic mice were skinned, 
eviscerated and intrascapular fat deposits removed. The embryos were then dehydrated 
in 95% ethanol overnight and then placed in acetone for further fatty tissue 
solubilization and tissue permeabilization. Two different staining procedures were used 
to stain the skeletons, the first, as described in McLeod et al. 94, and the second, as 
described in Rigueur and Lyons.93 After the staining was completed, the skulls were 
incubated in a solution of KOH in glycerol to enhance transparency and prevent collapse 
of the skulls. Once appropriate transparency was achieved the specimens were placed in 
a solution containing 1:1 glycerol/ethanol and images were taken.  
 
 
2.4 Image Capture and Analysis 
 
The investigator was blind to the genotype of embryos in each trial group. Ten 
litters (trials) consisting of a total of 39 mice were examined in this study. Images of 
stained heads in the sagittal and coronal view for each littermate were taken at 8x 
magnification using a Leica S6 D microscope and a Leica EC3 camera using the Leica 
Application Suite Software (Leica, Wetzlar, Germany). Scale calibration on the 
microscope was completed by using an image of a line gauge. The craniofacial skeleton 
of each stained head was analyzed using ImageJ software with four measurements 
being made. Measurements were excluded in embryos in which the skull was distorted 
(collapse of the cranial vault), a fractured bone segment was present, or if the landmark 
could not be identified. The first measurement, the anterior-posterior (AP) length, was 
recorded twice from two independent measurements one made in a sagittal viewpoint 
(Fig. 5A) and the other made in a coronal viewpoint (Fig. 5C). The AP length connects the 
most anterior portion of the premaxilla to the tangent of the most posterior portion of 
the exoccipital bone. The second measurement (transverse) also recorded twice from 
two independent measurements, one from the coronal and one from caudal viewpoint, 





measurement (mandibular length) is made in the sagittal view and connects the inferior-
distal condyle point to the most anterior-inferior point on the symphysis of the left 
mandible (Fig. 5C). The fourth measurement (intramandibular angle) is made in the 
caudal viewpoint (Fig. 5B) and is taken of the angle formed between the distal most 
points of angular processes with the midsymphysis being the common vertex. 
 
2.5 Toluidine Blue Staining 
 
Staining with toluidine blue allows the visualization of proteoglycan within the 
cartilage matrix and is used as a means of assessing cartilage formation. Toluidine blue 
is a cationic dye with high affinity for the negatively charged sulfate groups of 
proteoglycans. Nuclei and cartilage stain a deep violet color whereas other tissues stain 
a shade of pale blue. 
 Sagittal paraffins sections of E16 mouse skulls were prepared. Dewaxing of the 
sections was completed using xylenes followed by rehydration through a succession of 
decreasing concentrations of ethanol. Slides were stained using toluidine blue working 
solution for 5 mins, followed by a water wash until the solution runs clear. The slides 
were then dehydrated in a 37℃ oven for 20 mins. Xylene was used to clear the slides, 


































Figure 5: Representative microscope images of Alcian blue and Alizarin red embryo 
skulls stained in different viewpoints. Red measure lines represent the parameter 
evaluated in each viewpoint. Caudal viewpoint with mandibular angle and transverse 
parameters (A). Coronal viewpoint with AP and transverse parameters (B). Sagittal 










Immunohistochemistry was used to detect and localize three proteins: Sox9, 
Beta-catenin, and Osteocalcin, in the tissue of E16 mouse skulls. Sox9 is an essential 
regulator of chondrogenesis.66 Beta-catenin is a key downstream effector of GSK-3 
action on the Wnt/beta-catenin signalling pathway.20 Osteocalcin is a marker of bone 
development.95 The technique uses a two-step binding process; the first step employs a 
specific primary antibody to bind the antigenic region located on the protein of interest. 
The second step involves the binding of the primary antibody by a secondary antibody 
conjugated to the enzyme horseradish peroxidase (HRP). HRP catalyzes the reaction 
between the chromogen 3,3’-Diaminobenzidine (DAB) and hydrogen peroxide at the site 
in the tissue section where the protein is located. The product of the reaction is oxidized 
DAB which is an insoluble brown pigment that can be viewed under light microscopy.  
Sagittal paraffin sections (5μm thickness) of E16 mouse skulls were prepared. 
The process involves dewaxing the sections with xylenes and then rehydrating through a 
succession of decreasing concentration of ethanol. To block endogenous peroxidase 
from reacting with the chromogen and causing false positivity, a solution of hydrogen 
peroxide in methanol is used. During tissue processing the antigenic determinant 
(epitope) on the antigen can be imperceptible to antibodies, therefore 0.1% solution of 
the non-ionic detergent Triton X-100 is used to improve antigen accessibility and 
antibody binding. To reduce non-specific antibody binding, the tissue sections are 
preincubated in a saline and goat serum solution. Primary antibodies: goat polyclonal 
hSox9 (AF3075 R&D Systems), or rabbit polyclonal β-Catenin (bs-1165R Bioss 
Antibodies), or rabbit polyclonal Osteocalcin (ab93876 Abcam) are bound to the tissue 
section, overnight at 4°C. Removal of any unbound primary antibodies is achieved by 
successive phosphate buffer saline (PBS) washes. Suitable HRP-conjugated secondary 
antibodies are selected and added to the tissue in order to bind the primary antibodies. 





secondary antibodies. The remaining bound antibody-HRP complex is observed using a 
DAB staining kit (DAKO). As soon as color becomes evident the reaction is stopped by 
transferral of slides into water, followed by counterstaining with 0.5% methyl green and 
mounting with the xylene-based media ShurMount™. Light microscopy was performed 
using a Leica DM1000 microscope using Leica Application Suite Software (Leica, Wetzlar, 
Germany). 
 
2.7 Data Analysis 
 
Following data collection (Appendix A) of the measurements for each embryo, 
descriptive statistics including mean and standard deviation (SD) were calculated for 
each litter trial. The software Statistical Product and Service Solutions (SPSS) version 
27.0 (IBM Corporation, Armonk, NY, USA) was used to perform an Error Study and a 
Paired Samples T Test analysis. Statistical significance was set at P<0.05. Qualitative 






Chapter 3  
3 Results  
 
 
3.1 Error Study 
 
Due to a certain degree of subjectiveness involved when making two-
dimensional measurements of a three-dimensional mouse skull, an error study was first 
conducted to assess reliability of the examiner’s measurements. Test-retest reliability 
was assessed in terms intraclass correlation coefficient (ICC) using a two-way random 
effects model. ICC values range from 0-1.00; values above 0.90 indicate excellent 
reliability; those between 0.75-0.90 indicate good reliability; 0.50-0.75 have moderate 
reliability; and those below 0.5 have poor reliability 96. 
Data were gathered at two different time points 2 months apart to determine 
intra-examiner reliability. Table 1 shows ICC for each parameter measured by the 
examiner. The ICC values for all parameters ranged from 0.93 to 0.99. Excellent intra-
rater reliability was found for all parameters.  The lowest reliability (0.93) is seen with 
the transverse width measurements in the caudal viewpoint. The highest reliability 
(1.00) is seen in AP measurements in both coronal and caudal viewpoints and the 




AP (sagittal) 0.99 
AP (coronal) 0.99 
Transverse (coronal) 0.99 
Transverse (caudal) 0.93 
Mandibular Angle 0.95 
Mandible (sagittal) 0.95 
 








3.2 Craniofacial Skeleton Measurements 
 
A total of 10 trials with each trial consisting of embryos from the same litter 
were examined for skull and mandibular parameters. The number of embryos in each 
trial ranged from 2 to 8. Visual examination of the stained specimens by naked eye 
showed minimal differences between mutants and non-mutant skulls, whereas under 
microscopic examination the size discrepancy between the two groups could be 
distinguishable. Length of the craniofacial skeleton and the width of the cranial vault as 
well as mandibular parameters were assessed using Alcian Blue and Alizarin Red stained 
specimen under a microscope (Fig. 5). Following completion of the measurements, the 
genotype of each embryo was revealed (Appendix B) and the associated features for 
mutants (knock outs) vs nonmutants (control) was assessed. Genotypic wildtype and 
heterozygote mice were both grouped into the control mice category because data from 
this study showed no phenotypic differences between the two genotypes (Appendix C).  
Mean measurement for all parameters between KO mice and control mice for 
each trial were represented in scatterplots (Fig 9-14). The mean measurement, standard 
deviation (SD), differences between means, and P-value for each parameter between 
KO mice and control mice grouped amongst all trials is shown in Table 2. The values 
from Table 2 were plotted in a bar graph format in Appendix D. The difference in AP 
between the KOs and control mice across all trials was found to be significantly 








 Figure 6: Representative images from the sagittal view of GSK-3 KO embryo skull (A) and 





The mean reduction in size as measured in the transverse dimension was not as 
large as the AP dimension between the two groups. The mutants had a mean transverse 
dimension of 5.25mm while the wild type mean transverse width was 5.49mm. The two 
groups did not show a significant difference in transverse width in the coronal view, but 
did show a significant difference in the caudal view. 
 
 
 The greatest proportional reduction in size was seen in the mandibular AP 
length with a difference of 0.79mm between the two groups. Mandibular length was 
found to be significantly different with the control embryos having a mean mandibular 
length of 4.62mm and the mutants having a mean mandibular length of 3.83mm. The 
KO embryos also display a significantly greater angle between the hemi angular 
processes with a mean of 81.39° versus the control embryos, which have a mean of 
62.13°. The AP/Transverse ratio in the coronal viewpoint was found to be significantly 





Figure 7: Representative images from the coronal view of GSK-3 KO embryo skull 










Table 2: Mean measurement (+/- SD) of GSK-3 KO vs Control mice averaged over 10 









AP (sagittal) mm 7.37 (0.96)  8.30 (1.02) 0.93 <0.001* 
AP (coronal) mm 7.37 (0.94) 8.30 (1.05) 0.93 <0.001* 
Transverse (coronal) mm 5.25 (0.71) 5.49 (0.72) 0.24 0.06 
Transverse (caudal) mm 5.24 (0.72) 5.49 (0.72) 0.25 0.033* 
Mandible Length (sagittal) 
mm 
3.83 (0.46) 4.62 (0.48) 0.79 <0.001* 
Mandibular Angle (caudal) ° 81.39 (6.24) 62.13 (3.29) -19.26 <0.001* 
AP/Transverse (coronal) 1.41 (0.06) 1.51 (0.06) 0.10 <0.001* 
Figure 8: Representative images from the caudal view of GSK-3 KO embryo 







Figure 9:  Comparison of mean AP length between GSK-3 KO and control mice across 






Figure 10: Comparison of mean AP length between GSK-3 KO and control mice across 








Figure 11: Comparison of mean transverse width between GSK-3 KO and control mice 




Figure 12: Comparison of mean transverse width between GSK-3 KO and control mice 









Figure 13: Comparison of mean mandibular length between GSK-3 KO and control mice 






Figure 14: Comparison of mean mandibular angle between GSK-3 KO and control mice 









3.3 Qualitative Analysis of Toluidine Blue Stains and IHC 
 
To understand the significant differences seen in the observations between KO 
and control mice, histological analyses of the viscerocranium were performed using E16 
Toluidine Blue stained sections (Fig. 16). Histological slides stained by Toluidine Blue, a 
dye which has an affinity for acidic tissue components like proteoglycans and cartilage, 
showed observable differences in the viscerocranium between both groups. At E16 the 
palate of the control mice has closed compared to Gsk3a and Gsk3b KOs which display 
defective palatal growth and fusion. Primordia of the lower incisor appear to be 
unaffected in development in the GSK-3 KO mice. The mandibular section of the GSK-3 
KOs shows a noticeable reduction in the size of Meckel’s Cartilage when compared to 
the wild type embryonic mice at E16, a finding which is also duplicated in the IHC stains 
(Fig. 17). 
Immunohistochemistry was used to detect and localize the presence of Sox9, 
beta catenin, and osteocalcin in the mandibular cross section (Figure 17). The number of 
Sox9 positive cells appears greater in the control mice cross section compared to KO 
mice. The difference in the number of Sox9 positive cells is primarily observed in and 
around the lower incisor tooth primordia. Both groups show Sox9 positive cells localized 
in MC, however, there appears to be no difference in the relative number of stained 
cells between groups within the structure. Beta catenin positive cells appear to be 
diffuse in their location within the cross sections of both groups, with some particular 
localization in and around the vicinity of MC. There appears to be a difference in 
intensity of the beta catenin staining between the two groups with a reduced intensity 
seen in the KO group. The relative number of beta catenin stained cells in the KO group 
appears to be increased primarily in and around MC, whereas, the control group shows 
appears to show an increase in the number beta catenin stained cells in the lower 
incisor tooth primordia. Osteocalcin staining shows a pattern similar in localization to 
beta catenin with no apparent change in intensity of the stain between the groups. In 

























Figure 15: Microscope images of Toluidine Blue stained E16 KO and control 
embryo maxilla and mandible (n =1). Failure of palatal shelf (PS) fusion resulting 
in cleft (Cl) seen in KO mice (C). Meckel’s Cartilage (MC) seen distal to incisor 
tooth primordia (L1) and inferior to base of tongue (T) is smaller in size in KO 









Figure 16: Localized expression of Sox9 (A/D), Beta Catenin (B/E), and Osteocalcin 
(C/F) assessed in E16 GSK-3 KO and control embryo mandibles by IHC images (n=1). 























Chapter 4  
4 Discussion 
The aim of this study was to evaluate any changes that occur to the 
parameters of the craniofacial skeleton when both Gsk3a and Gsk3b are knocked 
out exclusively in mouse cartilage.  
  
4.1 Anterior-Posterior Craniofacial Size 
 
Previous literature has discussed the importance of GSK-3α and GSK-3β as key 
regulators of bone growth and normal skeletal development.67, 68 This study was novel in 
the approach of assessing the craniofacial effects of prenatal ablation of both GSK-3 
proteins in mouse cartilage. The anteroposterior dimension of the skull was most affected 
in absolute length with a reduction of 0.93mm between the two groups. The reduction of 
craniofacial AP size in GSK-3 KO mice is consistent with previous literature which also 
points to multiple defected craniofacial bones that are contributing to the total reduction 
of the AP size of global GSK-3 KO mice skulls. Szabo-Rogers et al. showed that in the 
absence of Gsk3b, frontal bone primordium exhibits cell apoptosis and reduced cell 
proliferation, leading to a reduction of frontal bone size.97 Liu et al. showed defects in the 
palatine process of the maxilla and palatine bones of Gsk3b KO mice resulting in cleft 
palate.29 We found similar results of incomplete closure of the palate when the maxillae 
of E16 Gsk3a and Gsk3b KO embryos were examined with Toluidine blue staining. 
Furthermore, the difference in AP length of the skull may be due to the mechanism of 
ossification of the cranial base bones. Sung-Won Jin et al. propose that the increase in AP 
length of the cranium is governed by the growth of the cranial base bones with active 
response at the coronal suture.98 The cranial base ossifies through endochondral 
ossification, a process, which Bali et al. has shown to be disrupted in juvenile cartilage-
specific GSK-3 KO mice resulting in shorter long bones.67 The origin of reduction in the AP 
size of the skull is difficult to determine on stained slides in our study due to differences 





that the AP length reduction in GSK-3 KO mice may have multiple sites of causal origin 
including the maxilla, frontal bone, and the cranial base bones. 
 
4.2 Mandibular Length  
 
Mandibular length was found to have the greatest proportional decrease out of 
all the parameters examined in the KO and control groups. The mean difference in the 
length of the mandible was 0.79mm which corresponds to a 1/6th reduction in mean AP 
length of the mandible in the KO group. To further investigate the significant difference 
seen in mandibular length, Toluidine blue staining and IHC were performed on KO and 
control mandibles. Toluidine blue sections at E16 show an observable difference in the 
size of Meckel’s cartilage between the two groups, with the GSK-3 KO group displaying a 
smaller MC (Fig. 15). Previous literature has shown that Meckel’s cartilage serves as a 
template for ossification and regulates the length of the mandible.51 This is consistent 
with our study’s finding of a reduced mandibular length in GSK-3 KO mice.  
Additionally, Lei et al. and Stewart et al., have demonstrated that faulty 
development of Meckel’s cartilage can result in cleft palate 76, 99; a finding which is also 
replicated in the Toluidine blue stains of GSK-3 KO mice in this study. Ricks et al. argues 
that normal development of MC promotes the AP extension of the mandible which 
successively allows the tongue to flatten and give way for the fusion of the palatal 
shelves.100 It is tempting to speculate that the failure of the palate to fuse in GSK-3 KO 
mice is due to defective growth of MC and the mandible. GSK-3’s intrinsic regulation in 
the process of palatogenesis has been demonstrated by He et al., and clefting has been 
observed in the palate of global GSK-3 KO mice.77 In this study, because the GSK-3 KO is 
cartilage-specific and the process of palatogenesis does not require a cartilage 
intermediate, we suspect that the palatal clefting observed in Gsk3a and Gsk3b KO mice 
is not due to defective intrinsic GSK-3 regulation in palatogenesis. 
IHC was completed to determine if a relationship between the GSK-3 regulated 





shorter mandibular length observed in GSK-3 KO mice. CNC-specific deletion of SOX-9 has 
been previously shown to result in the absence of Meckel’s cartilage and consequently 
shorter mandibles.51 Results of this study show the relative number of Sox9 positively 
stained cells in MC appears similar in both groups despite the size of MC being smaller in 
the KO group. A causal relationship between Sox9 and the size of MC cannot be 
determined in this study. Beta-catenin prenatal KO mutants have also been associated in 
severe truncation of MC as well as defective growth of the rostral process of the mandible 
and lower incisor.101 GSK-3 is a known negative mediator of Wnt/beta-catenin signaling 
20, thus an increase in beta-catenin positive cells was anticipated in GSK-3 KO mice. Beta 
catenin signaling, amongst other cellular processes, stimulates apoptosis in 
chondrocytes.102 An increase in beta-catenin positive cells appeared to occur around MC 
in KO mice, possibly signifying an increase in apoptosis of MC chondrocytes (Fig. 16E). 
Further experiments, such as TUNEL analysis may reveal whether an increase in apoptosis 
is present in MC of KO mice. This may explain the truncated size of MC observed in GSK-
3 KO mice. A decrease in beta-catenin positive cells appeared to occur in the lower incisor 
primordia of KO mice as well, this however, is likely due to the early developmental stage 
in which the lower incisor is in. Beta-catenin signaling is primarily required for the later 
tooth root formation stage.103 Osteocalcin is a protein secreted by osteoblasts that binds 
to calcium and concentrates in bone.104 It is used as a biomarker for bone formation and 
does not reach maximum levels until late mineralization stages.95 In vitro GSK-3 inhibition 
has been previously shown to enhance osteoblast differentiation and bone formation, 
thereby increasing levels of osteocalcin.81 Qualitative IHC analysis did not suggest a 
change in the osteocalcin staining in the cross section of the prenatal mouse mandible 
between the two groups. The absence of an observable change in osteocalcin staining is 
likely due to the timepoint, E16.5 may be too early in the mineralization process to show 
changes in osteocalcin levels. Another explanation may be the fact the KO of GSK-3 is 
occurring in chondrocytes. Intramembranous bone formation of the body of the mandible 
is affected less by the ablation, therefore, minimal change in osteocalcin levels would be 





is consistent with the current paradigm that a change in MC primarily effects the resultant 
size of the mandible and not the process of bone formation itself. This study did not 
evaluate condylar changes in the GSK-3 KO mice; thus, it is plausible that some of the 
reduction seen in mandibular length is due to defective endochondral ossification at the 
condylar head. 
 
4.3 Transverse Dimension  
 
The transverse dimension showed conflicting results in the coronal and caudal 
viewpoints despite the means of both viewpoints being nearly identical for the KO 
(5.25/5.24mm) and control (5.49/5.49mm) group. In the coronal view point the difference 
in mean transverse width was found not to be statistically significant, whereas the mean 
transverse width in the caudal viewpoint was statistically significant. In respect to the ICC, 
the least reliable measurement was the transverse width in the caudal viewpoint. The 
transverse values in the coronal viewpoint (P-value<0.001) are consistently more reliable 
and accurate than the mean transverse caudal viewpoint values (P-value=0.033). The 
developmental process of cranial vault ossification may provide an explanation for the 
milder effects observed on skull width than length. The transverse dimension was 
measured at the widest points of the skull, both points are located on the cranial vault’s 
parietal bones. The development of the cranial vault bones is primarily governed by 
intramembranous ossification 98, a process that, which unlike endochondral ossification, 
does not use a pre-existing cartilage template. In this study the KO of GSK-3 was 
performed in chondrocytes, which may explain why no significant difference was seen in 
the transverse dimension between KO and control embryos. 
 A significant difference was found in the AP/transverse ratio in the coronal 
viewpoint. The difference in ratios is primarily to due to change in the AP with minimal 
change in the transverse. Due to the severity of consequences associated with changes 





is also possible that a compensating mechanism may be at play in holding the cranial 
width. 
 
4.4  Hemi-mandibular angle 
 
  The increase in the hemi mandibular angle supports our theory of compensation 
to maintain the width of the craniofacial skeleton. The angular processes were chosen as 
landmarks because they were found to be more discernible in the caudal view as 
compared to the coronoid and condylar processes. Furthermore, growth of the angular 
processes is governed by chondrocyte mediated endochondral ossification.105 The angle 
formed between the angular processes of the mandible with a vertex at the symphysis 
was found to be significantly larger in KO embryos when compared to control embryos. 
Peripheral edema which has been noted in cardiac myocyte specific GSK-3 KO mice 106, 
could be affecting the cartilage specific GSK-3 KO mice in our study. It is possible that a 
fluid increase in the neck could be acting as a compressive force widening the mandible. 
We believe that the greater mandibular angle in KO embryos may be a feature of the 
aforementioned compensating mechanism to maintain the width of the craniofacial 
skeleton. Figure 17 outlines how the decrease in AP length is compensated by an increase 
in the mandibular angle to hold the transverse dimension of craniofacial skeleton. An 
increase in the mandibular width may act to hold the width of cranium via its articulation 
point at the temporomandibular joint cavity. Alternatively, it is also feasible that the 
transverse dimension of the cranium may be causing an increase in the mandibular angle 












4.5 Lower Incisor Primordia 
 
An interesting finding to note in the IHC slides is the development of the lower 
incisor tooth primordia in the GSK-3 KO group which appears to be delayed compared to 
the control group. All three proteins examined appear to exhibit relatively fewer stained 
cells/matrix in the lower incisor primordia for the GSK-3 KO group. Sox9, beta catenin, 
and osteocalcin have all been previously implicated as being essential in tooth 
development.107–109 Further evaluation of tooth developmental stage at different 
timepoints between control and KO mice would be needed to confirm that the GSK-3 KO 
Figure 17: Compensating mechanism of mandible from caudal view of 
GSK-3 KO mice mandible (blue) vs. Control (orange). As AP length 
decreases the mandibular angle increases to maintain the width at the 





produces a developmental delay in the lower incisor primordia. Further research of GSK-
3’s role in the development of teeth would be interesting to investigate. 
 
4.6 Clinical Significance  
 
GSK-3’s ability to modulate the craniofacial bones is clinically relevant in 
orthodontics. In order to achieve a functional and esthetic outcome in orthodontics the 
craniofacial skeleton must be in harmony. Too great of a skeletal discrepancy may 
produce a subpar esthetic outcome. Alternatively, a challenging attempt to camouflage 
the skeletal discrepancy may result in an unstable occlusion. Understanding how GSK-3 
can change the size of the craniofacial bones like the mandible may help orthodontists 
develop adjunctive treatment modalities to assist in the correction of skeletal 
discrepancies without the need for surgery. Several human diseases have been linked to 
faulty GSK-3 activity including gestational110 and type 2 diabetes6, Alzheimer’s and 
psychiatric disorders.6 This study provides a basis suggesting GSK-3’s involvement in 
micrognathia and cleft palate. Research evaluating GSK-3 inhibitors has also been on the 
rise. Studies involving administration of GSK-3 inhibitors in animal models of diabetes 
have shown positive results in normalizing blood glucose levels.111, 112 The prenatal 
evaluation of GSK-3 ablation on the craniofacial skeleton is important because a majority 
of congenital craniofacial anomalies manifest in utero. This study demonstrates possible 
prenatal craniofacial effects and consequences of delivering drugs that target GSK-3 
during pregnancy. Future research should focus on evaluating the effects of GSK-3 













4.7 Strengths and Limitations of the Study 
 
One of the strengths of this study involved the investigator being blinded to 
embryo genotypes prior to taking craniofacial measurements, which helped reduce 
investigator bias. Error study demonstrated strong ICC for all parameters indicating good 
reliability of measurements. A large trial size of 10 litters also ensured reliability of the 
measures. 
One of the weaknesses of this study lied in the validity of the measurements which 
could not be corroborated. There was a certain degree of subjectiveness on the 
investigators part when making measurements and accounting for yaw, pitch and roll of 
the skulls. Micro-CT would have assisted in the validity of the measurements. Other 
weaknesses included varying litter sizes (2-6) giving unequal weight to trial means. The 
study was conducted on mice as a result data needs to be extrapolated to humans. Sex 
effects were not considered since sexes cannot be distinguished morphologically at the 
examined age. In addition, further analyses on the molecular and cellular basis of the 
observed effects is required. We do not know the efficiency with which Cre catalyzed KO 
of the GSK-3 genes in the specific skeletal structures. On the other hand, recent reports 
of transdifferentiation of chondrocytes to osteoblasts113 raise the possibility that 





















The aim of this study was to assess the effect of chondrocyte specific deletion of Gsk3a 
and Gsk3b in embryonic mice on the size of the mandible and the antero-posterior (AP) 
and transverse size of the prenatal craniofacial skeleton at E18.5. It was found that: 
1. There was a significant reduction in AP size of the skull, and mandible in GSK-3 
KO mice. 
2. There was no significant change observed in the transverse dimension of the 
skull between the KO and control groups. 
3. The intramandibular angle between the right and left angular processes was 
significantly greater in the KO mice. 
4. At E16.5 GSK-3 KO mice display cleft palate and a reduction in size of Meckel’s 
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1-1 5.86 5.87 4 3.87 1.47 76.85 3.38 
1-2 5.46 5.61 3.87 3.75 1.45 107.6 3.08 
1-3 6.23 6.14 3.98 3.89 1.54 66.13 3.62 

























2-1 8.95 8.9 5.49 5.56 1.62 53.59 4.56 
2-2 8.62 8.64 5.33 5.4 1.62 NA 3.97 
2-3 8.15 8.23 5.59 5.57 1.47 NA NA 
2-4 8.04 7.83 5.72 5.77 1.37 76.43 3.69 
2-5 8.06 7.98 5.33 5.45 1.50 83.72 3.64 
2-6 8.92 8.82 5.41 5.36 1.63 67.3 4.99 
2-7 Excluded Excluded Excluded Excluded Excluded 67.47 4.74 

























3-1 8.01 8.09 5.41 5.4 1.50 65.38 4.8 
3-2 8.06 8.04 5.31 5.2 1.51 61.96 4.82 
3-3 6.95 6.93 4.7 4.81 1.47 84.09 4.18 
3-4 6.27 6.14 4.38 4.34 1.40 81.52 3.79 


































4-1 7.49 7.57 5.12 5.1 1.48 63.36 4.78 
4-2 7.65 7.69 5.38 5.3 1.43 66.04 4.97 
4-3 7.86 7.88 5.08 5.02 1.55 62.49 4.48 


























7.48 7.34 4.85 4.96 1.51 60.57 4.64 
5-2 

























6-1 7.67 7.69 5.41 5.48 1.42 55.1 4.78 

























7-1 7.76 7.83 5.52 5.44 1.42 82.64 3.86 
7-2 9.01 8.99 6.1 5.93 1.47 61.59 4.69 
7-3 8.56 8.6 5.77 5.46 1.49 86.64 4.14 
7-4 9.16 9.21 6.13 6.09 1.50 Excluded 4.79 
7-5 8.47 8.36 6.17 6.14 1.35 85.75 3.4 

































8-1 9.65 9.73 6.65 6.69 1.46 61.86 3.99 
8-2 9 9.3 6.54 6.49 1.42 60.04 Excluded 
8-3 8.06 8.14 5.73 5.76 1.42 81.2 3.02 
8-4 8.31 8.26 5.78 5.82 1.43 77.79 Excluded 
 
Trial 9 





















9-1 8.4 8.38 6.04 5.99 1.39 75.23 4.49 

























10-1 8.19 8.21 6.02 6.04 1.36 76.05 4.37 


























Appendix B: Genotypes for individual embryos determined from PCR 
 
Note: Both C and Het are used as controls in skeletal stains, they are indistinguishable 
from each other by eye.  
 
Trial Embryo Genotype Status 
1 1-1 GSK3αffβffCol2a1cre+/- KO 
 1-2 GSK3αffβffCol2a1cre+/- KO 
 1-3 GSK3αffβff C 
 1-4 GSK3αf+βff C 
 1-5 GSK3αf+βff C 
2 2-1 GSK3αf+βff C 
 2-2 GSK3αffβffCol2a1cre+/- KO 
 2-3 GSK3αffβffCol2a1cre+/- KO 
 2-4 GSK3αffβffCol2a1cre+/- KO 
 2-5 GSK3αffβff C 
3 3-1 GSK3αf+βffCol2a1cre+/- Het 
 3-2 GSK3αf+βffCol2a1cre+/- Het 
 3-3 GSK3αffβffCol2a1cre+/- KO 
 3-4 GSK3αffβffCol2a1cre+/- KO 
 3-5 GSK3αffβffCol2a1cre+/- KO 
4 4-1 GSK3αf+βff C 
 4-2 GSK3αf+βffCol2a1cre+/- Het 
 4-3 GSK3αf+βffCol2a1cre+/- Het 
 4-4 GSK3αffβffCol2a1cre+/- KO 
5 5-1 GSK3αffβff C 
 5-2 GSK3αffβffCol2a1cre+/- KO 
6 6-1 GSK3αf+βff C 
 6-2 GSK3αffβffCol2a1cre+/- KO 
7 7-1 GSK3αffβffCol2a1cre+/- KO 
 7-2 GSK3αf+βffCol2a1cre+/- Het 
 7-3 GSK3αffβffCol2a1cre+/- KO 
 7-4 GSK3αf+βff C 
 7-5 GSK3αffβffCol2a1cre+/- KO 
 7-6 GSK3αf+βff C 
8 8-1 GSK3αffβff C 
  8-2 GSK3αf+βffCol2a1cre+/- Het 
  8-3 GSK3αffβffCol2a1cre+/- KO 
  8-4 (GSK3αffβffCol2a1cre+/-) KO 
9 9-1 GSK3αffβffCol2a1cre+/- KO 
 9-2 GSK3αffβff C 
10 10-1 GSK3αffβffCol2a1cre+/- KO 

























































AP (sagittal) mm 8.36 (0.56) 8.28 (1.12) 0.86 
AP (coronal) mm 8.43 (0.60) 8.26 (1.14) 0.73 
Transverse (coronal) mm 5.69 (0.49) 5.38 (0.76) 0.36 
Transverse (caudal) mm 5.62 (0.49) 5.39 (0.77) 0.51 
Mandible Length (sagittal) 
mm 
4.81 (0.19) 4.49 (0.50) 0.17 
Mandibular Angle (caudal) 
° 
63.08 (2.00) 62.61 (4.78) 0.81 





Appendix D: Bar graphs for KO and Control mice mean measurements of parameters 
across all trials 
 
 













Comparison of mean transverse width between GSK-3 KO and control mice in the 
coronal viewpoint. 
 
























Appendix E: Mean measurement for each craniofacial parameter evaluated between 
GSK-3 KO and control mice for trials 1-10 
 
Trial 1  
KO Mean Control Mean 
AP (sagittal) mm 5.66 6.35 
AP (coronal) mm 5.74 6.29 
Transverse (coronal) mm 3.94 4.05 
Transverse (caudal) mm 3.81 4.02 
AP/Transverse (coronal) 1.46 1.55 
Mandibular Angle (caudal) ° 92.23 67.05 




Trial 2  
KO Mean Control Mean 
AP (sagittal) mm 8.05 8.83 
AP (coronal) mm 8.02 8.79 
Transverse (coronal) mm 5.45 5.41 
Transverse (caudal) mm 5.51 5.44 
AP/Transverse (coronal) 1.47 1.62 
Mandibular Angle (caudal) ° 79.00 62.79 




Trial 3  
KO Mean Control Mean 
AP (sagittal) mm 6.54 8.04 
AP (coronal) mm 6.51 8.06 
Transverse (coronal) mm 4.43 5.36 
Transverse (caudal) mm 4.48 5.30 
AP/Transverse (coronal) 1.47 1.50 
Mandibular Angle (caudal) ° 82.73 63.67 











Trial 4  
KO Mean Control Mean 
AP (sagittal) mm 6.99 7.67 
AP (coronal) mm 6.91 7.71 
Transverse (coronal) mm 4.98 5.19 
Transverse (caudal) mm 4.95 5.14 
AP/Transverse (coronal) 1.39 1.49 
Mandibular Angle (caudal) ° 90.08 63.96 





Trial 5  
KO Mean Control Mean 
AP (sagittal) mm 6.73 7.48 
AP (coronal) mm 6.84 7.34 
Transverse (coronal) mm 4.76 4.85 
Transverse (caudal) mm 4.89 4.96 
AP/Transverse (coronal)  1.44 1.51 
Mandibular Angle (caudal) ° 80.77 60.57 





Trial 6 KO Mean Control Mean 
AP (sagittal) mm 6.66 7.67 
AP (coronal) mm 6.67 7.69 
Transverse (coronal) mm 5.29 5.41 
Transverse (caudal) mm 5.27 5.48 
AP/Transverse (coronal) 1.26 1.42 
Mandibular Angle (caudal) ° 73.27 55.1 













Trial 7  
KO Mean Control Mean 
AP (sagittal) mm 8.26 9.12 
AP (coronal) mm 8.26 9.11 
Transverse (coronal) mm 5.82 6.12 
Transverse (caudal) mm  5.68 6.02 
AP/Transverse (coronal)  1.42 1.49 
Mandibular Angle (caudal) ° 85.01 63.76 




Trial 8  
KO Mean Control Mean 
AP (sagittal) mm 8.19 9.33 
AP (coronal) mm 8.2 9.512 
Transverse (coronal) mm 5.76 6.60 
Transverse (caudal) mm 5.79 6.59 
AP/Transverse (coronal) 1.42 1.44 
Mandibular Angle (caudal) ° 79.50 60.95 




Trial 9  
KO Mean Control Mean 
AP (sagittal) mm 8.4 9.53 
AP (coronal) mm 8.38 9.48 
Transverse (coronal) mm 6.04 5.91 
Transverse (caudal) mm 5.99 5.99 
AP/Transverse (coronal) 1.40 1.60 
Mandibular Angle (caudal) ° 75.23 59.38 













Trial 10  
KO Mean Control Mean 
AP (sagittal) mm 8.19 8.96 
AP (coronal) mm 8.21 9.01 
Transverse (coronal) mm 6.02 6.04 
Transverse (caudal) mm 6.04 6.01 
AP/Transverse (coronal) 1.37 1.49 
Mandibular Angle (caudal) ° 76.05 64.04 
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